Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development
Elmentve itt :
Szerzők: |
Pallagi Edina Ismail Ruba Paál Tamás Pannonhalminé Csóka Ildikó |
---|---|
Dokumentumtípus: | Cikk |
Megjelent: |
2018
|
Sorozat: | EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
122 |
doi: | 10.1016/j.ejps.2018.07.003 |
mtmt: | 3393606 |
Online Access: | http://publicatio.bibl.u-szeged.hu/14516 |
Hasonló tételek
-
Pegylation and formulation strategy of Anti-Microbial Peptide (AMP) according to the quality by design approach
Szerző: Manteghi Reihaneh, et al.
Megjelent: (2020) -
Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach.
Szerző: Bartos Csilla, et al.
Megjelent: (2018) -
Quality by Design driven development of Liraglutide loaded nanocarrier system designed for oral delivery
Szerző: Ismail Ruba, et al.
Megjelent: (2019) -
Novel strategies in the oral delivery of antidiabetic peptide drugs – Insulin, GLP 1 and its analogs
Szerző: Ismail Ruba, et al.
Megjelent: (2017) -
Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation
Szerző: Pallagi Edina, et al.
Megjelent: (2015)